HZT-501 (DUEXIS^®; ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis

References

• Gaziano JM. Nonnarcotic analgesics and hypertension. Am. J. Cardiol.97, 10–16 (2006).
   PubMed Web of Science ®Google Scholar
• Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve. Clin. J. Med.69(Suppl. 1), SI31–SI39 (2002).
   PubMedGoogle Scholar
• Biederman RE. Pharmacology in rehabilitation: nonsteroidal anti-inflammatory agents. J. Orthop. Sports Phys. Ther.35(6), 356–367 (2005).
   PubMedGoogle Scholar
• Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am. Fam. Physician80(12), 1371–1378 (2009).
   PubMed Web of Science ®Google Scholar
• Laine L. GI risk and risk factors of NSAIDs. J. Cardiovasc. Pharmacol.47(Suppl. 1), S60–S66 (2006).
   Web of Science ®Google Scholar
• Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf.29(2), 119–132 (2006).
   PubMed Web of Science ®Google Scholar
• Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol.104(3), 728–738 (2009).
   PubMed Web of Science ®Google Scholar
• Cryer B. NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality. Am. J. Gastroenterol.100, 1694–1695 (2005).
   PubMed Web of Science ®Google Scholar
• Tarone RE, Blot WJ, McLaughlin JK. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am. J. Ther.11(1), 17–25 (2004).
   PubMedGoogle Scholar
• Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J. Rheumatol.26(Suppl.), 18–24 (1999).
   Web of Science ®Google Scholar
• Straube S, Tramèr MR, Moore RA et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol.9, 41 (2009).
   PubMedGoogle Scholar
• Lanas A, García-Rodríguez LA, Polo-Tomás M et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am. J. Gastroenterol.104(7), 1633–1641 (2009).
   PubMed Web of Science ®Google Scholar
• Rahme E, Joseph L, Kong SX et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum.43(4), 917–924 (2000).
   PubMed Web of Science ®Google Scholar
• Smalley WE, Griffin MR, Fought RL et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J. Gen. Intern. Med.11(8), 461–469 (1996).
   PubMed Web of Science ®Google Scholar
• Peura DA. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am. J. Med.117(Suppl. 5A), S63–S71 (2004).
   Google Scholar
• Abdrabbo MK, Peura DA. NSAID-associated GI complications: available management options and identification of high-risk patients. Gastroenterl. Endo. News2, 65–68 (2004).
   Google Scholar
• Chan FK, Abraham NS, Scheiman JM et al. First international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am. J. Gastroenterol.103, 2908–2918 (2008).
   PubMed Web of Science ®Google Scholar
• Flood J. The role of acetaminophen in the treatment of osteoarthritis. Am. J. Manag. Care16(Suppl. Management), S48–S54 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann. Rheum. Dis.63(8), 901–907 (2004).
   PubMed Web of Science ®Google Scholar
• Towheed TE, Maxwell L, Judd MG et al. Acetaminophen for osteoarthritis. Cochrane Database Syst. Rev.1, CD004257 (2006).
   PubMed Web of Science ®Google Scholar
• Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst. Rev.4, Update CD002296 (2002).
   Google Scholar
• Brown T J, Hooper L, Elliott R A et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modeling. Health Technol. Assess.10(38), iii–iv, xi–xiii, 1–183 (2006).
   Web of Science ®Google Scholar
• Hawkey CJ, Karrasch JA, Szczepañski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. NEJM338(11), 727–734 (1998).
   PubMed Web of Science ®Google Scholar
• Rostom A, Wells G, Tugwell P et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst. Rev.4, CD002296 (2000).
   Google Scholar
• Hooper L, Brown TJ, Elliott R et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ329(7472), 948 (2004).
   PubMed Web of Science ®Google Scholar
• Lanas A, García-Rodríguez LA, Arroyo MT et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol.102(3), 507–515 (2007).
   PubMed Web of Science ®Google Scholar
• Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ180(7), 699–700 (2009).
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet374, 989–997 (2009).
   PubMed Web of Science ®Google Scholar
• Tsukahara K, Kimura K, Morita S et al. Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. J. Cardiol.57, 275–282 (2011).
   PubMedGoogle Scholar
• Fontes-Carvalho R, Albuquerque A, Araújo C et al. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur. J. Gastroenterol. Hepatol.23, 396–404 (2011).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost.101, 714–719 (2009).
   PubMed Web of Science ®Google Scholar
• Oyetayo OO, Talbert RL. Proton pump inhibitors and clopidogrel: is it a significant drug interaction? Expert Opin. Drug Saf.9, 593–602 (2010).
   PubMed Web of Science ®Google Scholar
• Disney BR, Watson RD, Blann AD et al. Review article: proton pump inhibitors with clopidogrel-evidence for and against a clinically-important interaction. Aliment. Pharmacol. Ther.33, 758–767 (2011).
   PubMedGoogle Scholar
• Gerhard T. Clopidogrel and proton pump inhibitors: a clinically meaningful interaction? Pharmacoepidemiol. Drug Saf.20, 214–218 (2011).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF et al. COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med.363, 1909–1917 (2010).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Jilma B, Schrör K et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J. Thromb. Haemost.8, 2624–2641 (2010).
   PubMed Web of Science ®Google Scholar
• Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ179(4), 319–326 (2008).
   PubMed Web of Science ®Google Scholar
• Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardio. Rev.17(4), 198–200 (2009).
   PubMed Web of Science ®Google Scholar
• Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology139(4), 1115–1127 (2010).
   PubMed Web of Science ®Google Scholar
• Rostom A, Muir K, Dubé C et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane collaboration systematic review. Clin. Gastroenterol. Hepatol.5(7), 818–828, (2007).
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med.8, e1001098 (2011).
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin. Pharmacol. Toxicol.98, 266–274 (2006).
   PubMed Web of Science ®Google Scholar
• Sturkenboom MC, Burke T, Tangelder M et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther.18(11–12), 1137–1147 (2003).
   PubMed Web of Science ®Google Scholar
• Bocanegra TS, Weaver AL, Tindall EA et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. J. Rheumatol.25(8), 1602–1611 (1998).
   PubMedGoogle Scholar
• Lai KC, Chu KM, Hui WM et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am. J. Med.118(11), 1271–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Hochberg MC, Fort JG et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment. Pharmacol. Ther.32(3), 401–413 (2010).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Schiff M, Genovese M et al. Significant reduction in upper gastrointestinal (UGI) ulcers with HZT-501, a single-tablet combination of ibuprofen-famotidine, the Reduce 1 and 2 Trials. Ann. Rheum. Dis.68(Suppl. 3), 704 (2009).
   Google Scholar
• Lee P, Anderson JA, Miller J et al. Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis. J. Rheumatol.3(3), 283–294 (1976).
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Cattaruzzi C, Troncon MG et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch. Intern. Med.158(1), 33–39 (1998).
   PubMed Web of Science ®Google Scholar
• Langman MJ, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet343(8905), 1075–1078 (1994).
   PubMed Web of Science ®Google Scholar
• Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int. J. Clin. Pract. Suppl. (135), 43–49 (2003).
   PubMedGoogle Scholar
• Stürmer T, Erb A, Keller F et al. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am. J. Med.111(7), 521–527 (2001).
   PubMedGoogle Scholar
• Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am. J. Epidemiology151(5), 488–496 (2000).
   PubMed Web of Science ®Google Scholar
• Baumgartner H, Schwarz HA, Blum W et al. Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations. Curr. Med. Res. Opin.13(8), 435–444 (1996).
   PubMed Web of Science ®Google Scholar
• Boureau F, Schneid H, Zeghari N et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann. Rheum. Dis.63(9), 1028–1034 (2004).
   PubMed Web of Science ®Google Scholar
• Day R, Morrison B, Luza A et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/ibuprofen Comparator Study Group. Arch. Intern. Med.160(12), 1781–1787 (2000).
   PubMed Web of Science ®Google Scholar
• Puopolo A, Boice JA, Fidelholtz JL et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage15(12), 1348–1356 (2007).
   PubMed Web of Science ®Google Scholar
• Wiesenhutter CW, Boice JA, Ko A et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo. Clin. Proc.80(4), 470–479 (2005).
   PubMed Web of Science ®Google Scholar
• Bank S, Blumstein M, Greenberg R et al. Efficacy of famotidine in the healing of active benign gastric ulceration: comparison of nonsteroidal anti-inflammatory- or aspirin-induced gastric ulcer and idiopathic gastric ulceration. Long Island Jewish Medical Center Acid-Peptic Study Group. Clin. Ther.15(1), 36–45 (1993).
   PubMedGoogle Scholar
• Taha AS, Hudson N, Hawkey CJ et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N. Engl. J. Med.334(22), 1435–1439 (1996).
   PubMed Web of Science ®Google Scholar
• Hudson N, Taha A, Russell R et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology112(6), 1817–1822 (1997).
   PubMed Web of Science ®Google Scholar
• Taha AS, McCloskey C, Prasad R et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a Phase III, randomised, double-blind, placebo-controlled trial. Lancet374(9684), 119–125 (2009).
   PubMed Web of Science ®Google Scholar
• Motrin®, prescribing information, McNeil Consumer Pharmaceuticals Co., Fort Washington, PA, USA (2003).
   Google Scholar
• Pepcid®, prescribing information, McNeil Consumer Pharmaceuticals Co., Fort Washington, PA, USA (2008).
   Google Scholar
• Vane JR. Introduction: mechanism of action of NSAIDs. Br. J. Rheumatol.35(Suppl. 1), 1–3 (1996).
   PubMedGoogle Scholar
• Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res.2(5), 379–85 (2000).
   PubMedGoogle Scholar
• Moore RA, Moore OA, Derry S et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann. Rheum. Dis.69(2), 374–379 (2010).
   PubMed Web of Science ®Google Scholar
• Langtry HD, Grant SM, Goa KL. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs38(4), 551–590 (1989).
   PubMed Web of Science ®Google Scholar
• Savarino V, Picciotto A, Magnolia MR et al. Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring. J. Clin. Pharmacol.27(10), 790–793 (1987).
   PubMedGoogle Scholar
• Tidmarsh G, Rodriguez SB. Famotidine (FAM) administered orally three times daily (tid) produces better gastric acid suppression and control than does twice daily (bid) administration of the same total daily dose. Presented at: Digestive Disease Week. Chicago, IL, USA, 30 May–4 June 2009 (Abstract T1971).
   Google Scholar
• Tidmarsh G, Rodriguez SB. HZT-501, a novel combination of ibuprofen (IBU) and famotidine (FAM), provides pharmacokinetics comparable to that of commercially available IBU and FAM in a patient-friendly dosing form: evaluation in healthy and renally-impaired subjects. Presented at: Digestive Disease Week. Chicago, IL, USA, 30 May–4 June 2009 (Abstract T1974).
   Google Scholar
• House AA, Silva Oliveira S, Ronco C. Anti-inflammatory drugs and the kidney. Int. J. Artif. Organs30(12), 1042–1046 (2007).
   PubMedGoogle Scholar
• Adhiyaman V, Asghar M, Oke A, White AD, Shah IU. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J. R. Soc. Med.94, 512–514 (2001).
   PubMed Web of Science ®Google Scholar
• Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin. Gastroenterol. Hepatol.3(5), 489–498 (2005).
   PubMed Web of Science ®Google Scholar
• Laine L, Schiff M, Genovese M et al. Independent predictors for the development of upper gastrointestinal ulcers: results from two 24-week double-blind trials of a single-tablet combination of ibuprofen-famotidine vs. ibuprofen alone (REDUCE-1 and 2). Digestive Disease Week. Chicago, IL, USA, 30 May–4 June 2009 (Abstract 407).
   Google Scholar
• Weinblatt ME, Genovese MC, Kivitz AJ et al. Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin, a single-tablet combination of ibuprofen-famotidine: results of two Phase 3 trials. Presented at: American College of Rheumatology Annual Scientific Meeting. Atlanta, GA , USA, 7–11 November 2010.
   Google Scholar
• Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clin. Ther.18(1), 36–54 (1996).
   PubMed Web of Science ®Google Scholar
• Schiff MH, Genovese MC, Kivitz MC et al. Long-term safety of an NSAID with built-in gastroprotection for treatment of pain and inflammation related to OA and RA: results from a one-year safety trial of a single-tablet combination of ibuprofen-famotidine vs ibuprofen alone. Arthritis Rheum.62(Suppl. 10), 946 (2009).
   Google Scholar
• Bushra R, Aslam N. An overview of clinical pharmacology of ibuprofen. Oman Med. J.25(3), 155–161 (2010).
   PubMedGoogle Scholar
• Gutthann SP, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology8(1), 18–24 (1997).
   PubMed Web of Science ®Google Scholar
• Singh G, Rosen RD. NSAID induced gastrointestinal complications: the ARAMIS perspective – 1997. Arthritis, Rheumatism, and Aging Medical Information System. J. Rheumatol.51(Suppl.), 8–16 (1998).
   Google Scholar
• Graham DY, White RH, Moreland LW et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann. Intern. Med.119, 257–262 (1993).
   PubMed Web of Science ®Google Scholar
• Spiegel BMR, Farid M, Dulai GS et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am. J. Med.119(5), e27–e36 (2006).
   Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med.120(8), 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Monguió R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics21(9), 623–650 (2003).
   PubMed Web of Science ®Google Scholar
• Leveille SG, Jones RN, Kiely DK et al. Chronic musculoskeletal pain and the occurrence of falls in an older population. JAMA302(20), 2214–2221 (2009).
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Manchikanti KN, Cash KA et al. Age-related prevalence of facet-joint involvement in chronic neck and low back pain. Pain Physician11(1), 67–75 (2008).
   PubMed Web of Science ®Google Scholar
• Cassou B, Derriennic F, Monfort C et al. Chronic neck and shoulder pain, age, and working conditions: longitudinal results from a large random sample in France. Occup. Environ. Med.59(8), 537–544 (2002).
   PubMed Web of Science ®Google Scholar
• Tielemans MM, Eikendal T, Jansen JB et al. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf.33(6), 443–453 (2010).
   PubMedGoogle Scholar
• Hansen JM, Hallas J, Lauritsen JM et al. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand. J. Gastroenterol.31(2), 126–130 (1996).
   PubMed Web of Science ®Google Scholar